Pioneering Drug Discovery for Cardiometabolic Diseases
Afimmune is a drug discovery and development company focused on the development of bioactive lipids for the treatment of cardiovascular and metabolic diseases.
Afimmune, headquartered in Dublin, Ireland, is a drug discovery and development company working on new medicines to improve the quality of life for people with diseases for which existing therapies are ineffective or unsafe. Afimmune has assets in various stages of clinical and pre-clinical development.
Afimmune pipeline
Data from Phase IIa show potent effect of Epeleuton on Triglyceride and HbA1C levels Dublin, Ireland, 23rd September 2020 – Afimmune, a clinical stage drug discovery […]
Dublin, Ireland, 14th November 2019 – Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that results of its investigational drug Epeleuton will be presented at […]
The article can be found below. Treatment and prevention of cardiovascular disease The potential of next generation omega-3 fatty acids In 2019 approximately 17.3 million […]